A Prospective Evaluation of Tocilizumab in Patients With Rheumatoid Arthritis Refractory to Conventional Disease-Modifying Anti-Rheumatic Medications (DMARDs)
Tocilizumab is a highly effective and generally well-tolerated treatment option for RA patients unresponsive to csDMARDs, though longer follow-up and controlled comparisons are needed to confirm long-term safety and causality.
Authors
- Abdullah Elrefae (ORCID: https://orcid.org/0000-0002-3739-4045)
- Murad Ali (ORCID: https://orcid.org/0000-0001-8910-8330)
- Khawaja Faizan Ejaz
- Shahid Khan (ORCID: https://orcid.org/0000-0003-2937-3831)
- Jazba Yousaf
- Monther Qandeel (ORCID: https://orcid.org/0000-0002-7176-4214)
- Rehan Wani (ORCID: https://orcid.org/0000-0001-5338-7809)
- Ammarah Amjad
- Maria Khurshid
- Muhammad Iftikhar Khattak
- Sajid Naseem
Institutions
- Ayub Medical College (PK)
- University of Azad Jammu and Kashmir (PK)
- Rawalpindi Medical University (PK)
- Russells Hall Hospital (GB)
- Hospital de Base (BR)
- Holy Family Hospital (PK)
- Central Middlesex Hospital (GB)
- Pakistan Institute of Medical Sciences (PK)
- Institute of Medical Sciences (IN)
Publication Details
- Journal
- Cureus
- Published
- 2025-09-22
- DOI
- https://doi.org/10.7759/cureus.92922
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00